Search | Clinical Trials Finder

Conditions: Dermatitis, Atopic
Interventions: Bermekimab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Indianapolis, Indiana • Chesterfield, Michigan • Tulsa, Oklahoma + 2 more

Conditions: Acquired Bleeding Disorder, Trauma
Interventions: eptacog alfa (activated), placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Healthy Participants
Interventions: AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Osteogenesis Imperfecta
Interventions: AGA2115, Placebo; Drug
Lead sponsor: Angitia Incorporated Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lake Forest, California

Conditions: Bacterial Infections
Interventions: KSP-1007, Placebo:0.9% sodium chloride, Meropenem; Drug · Other
Lead sponsor: Sumitovant Biopharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Intermittent Claudication
Interventions: Trans sodium crocetinate (TSC), 0.9% normal saline; Drug
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 40 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Birmingham, Alabama • Santa Rosa, California • Stanford, California + 4 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Placebo, LFG316; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Phoenix, Arizona • Winter Haven, Florida • Cleveland, Ohio

Conditions: Ulcerative Colitis
Interventions: Andecaliximab, Placebo to match Andecaliximab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Monroe, Louisiana • Bethesda, Maryland • Chesterfield Township, MI 48047, Michigan + 3 more

Conditions: Atopic Dermatitis
Interventions: FB825, Placebo; Biological · Other
Lead sponsor: Oneness Biotech Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 18
States / cities: Beverly Hills, California • Encino, California • Huntington Beach, California + 13 more

Conditions: Non-small Cell Lung Cancer
Interventions: Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo; Biological · Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 1,513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 49
States / cities: Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more

Conditions: Viral Disease
Interventions: PF-07304814, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Mountain View, California • Newport Beach, California • Sacramento, California + 2 more

Conditions: Chronic Hepatitis B
Interventions: ARC-520, Placebo, Entecavir, Tenofovir, diphenhydramine; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: San Francisco, California • Miami, Florida • New York, New York + 1 more

Conditions: Healthy Volunteers
Interventions: SAR441344, placebo, Keyhole limpet hemocyanin; Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Progressive Supranuclear Palsy
Interventions: Placebo, ABBV-8E12; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 40 Years and older
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 27
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 22 more

Conditions: Multiple Sclerosis
Interventions: ketamine; Drug
Lead sponsor: Alta Bates Summit Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Prostatectomy, Pain
Interventions: Acetaminophen (Ofirmev), Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Male and Female Japanese Volunteers
Interventions: NXL104, CAZ104, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Asthma
Interventions: QBX258, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 15
States / cities: Anaheim, California • Riverside, California • Rolling Hills Estates, California + 11 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: ASP5094, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Anniston, Alabama • DeBary, Florida • Jacksonville, Florida + 4 more

Conditions: Crohn's Disease
Interventions: Brazikumab IV Infusion, Brazikumab SC Injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 52
States / cities: Phoenix, Arizona • Lone Tree, Colorado • Clearwater, Florida + 25 more

Conditions: Healthy Subjects
Interventions: E5555; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Alzheimer Disease
Interventions: MK-2214, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Glendale, California • Los Alamitos, California • Orange, California + 9 more

Conditions: Pulmonary Sarcoidosis
Interventions: Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo; Biological
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Northridge, California • Denver, Colorado + 11 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Ala-Cpn10, Placebo; Biological · Drug
Lead sponsor: Invion, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Miami, Florida • Chicago, Illinois • Altoona, Pennsylvania + 3 more

Search by objective public record fields.

A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

Ketamine for MS Fatigue

Pharmacoeconomics and Related Patient Outcomes of Multi-dose Intravenous Acetaminophen (OFIRMEV)

A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.